Company / Operating Income
Xeris Biopharma Holdings, Inc. Operating Income History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$24.9M
FY2025
5-year range
-$115.2M / $24.9M
FY2021-FY2025
Trend
+174.0%
vs FY2024
Sector context
#51 of 204
Health Care
What the data says
Xeris Biopharma Holdings, Inc.'s operating income of $25M is higher than 75% of companies in the Health Care sector (FY2025). Operating Income has increased for 3 consecutive years, from -$115M in FY2022 to $25M in FY2025.
Based on SEC 10-K filings.
$25M in FY2025. Top quartile in the Health Care sector.
Improved from -$44M to $25M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 25% in Health CareTop 25% of 204This company $24.9M Sector average $107.7M
▼
-76.9% below sector average
Key checks
Key Insights
- Xeris Biopharma Holdings, Inc.'s operating income has grown for 3 consecutive years.
- In FY2025, operating income increased 174.0% year-over-year.
- Ranks #51 out of 204 companies in the Health Care sector.
- Lowest operating income in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $24.9M | +174.0% |
| FY2024 | -$33.6M | +23.5% |
| FY2023 | -$44.0M | +61.8% |
| FY2022 | -$115.2M | +0.0% |
| FY2021 | -$115.2M | -37.8% |
| FY2020 | -$83.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026